Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO plus ATRA and idarubicin vs AIDA in high-risk acute promyelocytic leukemia
2015-001151-68Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of arsenic trioxide in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Event-free survival. Started Dec 2015; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2015-001151-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001151-68.